Americans Sue GLP-1 Drug Makers Over Alleged NAION Risk Warnings

Wilmington, NC, September 22, 2026 —

Personal injury lawsuits have been filed by Americans against the manufacturers of widely used GLP-1 drugs, including Ozempic, Wegovy, and Mounjaro. The plaintiffs allege that these drug makers failed to provide adequate warnings regarding the potential risk of a rare vision loss condition known as NAION (Non-arteritic anterior ischemic optic neuropathy).

Researchers are currently investigating whether a link exists between the use of these popular medications and the development of NAION. However, scientific consensus has not yet established causation, and the occurrence of this vision loss condition is considered rare.

Representatives for the drug manufacturers have stated that the lawsuits are without merit. The U.S. Food and Drug Administration (FDA) is reportedly monitoring the situation as it unfolds.

In parallel with the ongoing investigations and legal actions in the United States, some international regulatory bodies have taken steps to address the alleged side effect. These international agencies have reportedly added warnings to their respective drug labeling concerning the potential for NAION in patients using these GLP-1 agonists.

The specific names of the manufacturers involved in the lawsuits, as well as the precise timeline or details of the legal filings, were not provided in the available summary. Similarly, information regarding the scope of the alleged vision loss or any specific patient outcomes was not detailed. The financial or legal implications for the manufacturers or patients remain subject to the ongoing legal processes and scientific review.

Story summarized from the original created by ABC News on www.wwaytv3.com, see more information here.